ClinicalTrials.gg
Not yet recruitingNCT07298590Updated Dec 23, 2025

An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease

An Early Phase 1 interventional study of CD19/BCMA CAR NK in IgG4 Related Disease, sponsored by Changhai Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Changhai Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
30th of 37
18 · median 58
Started
2025
with 7 others
Phase 1
11 of 41
7 open now
Primary completion
2028-06
later than 17 of 27 live
Registered
34th of 41
by date
Lead sponsor
2 of 41
Changhai Hospital

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 30th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 1, reaches primary completion later than 17 of the 27 other live ones, and was the 34th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.

03

Conditions studied

  • IgG4 Related Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be able to understand and provide and be willing to comply with study procedures and follow-up.
  2. The age at the time of signing the informed consent must be at least 18 years old and no more than 70 years old.
  3. Meet the 2020 Japanese criteria or ACR/EULAR IgG4-RD classification criteria.
  4. Subjects with active IgG4-RD at screening on an IgG4-RD RI ≥4, simultaneously meeting the following definitions of relapse or refractory disease:

    1. Definitions of relapse: subjects with IgG4-RD achieved remission after treatment but was active again before screening, and were classified as a high-risk group for recurrence assessed by assessment committee ;
    2. Definitions of before screening: subjects had used or glucocorticoids combined with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) (including cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, elorimod, thalidomide, etc.), or at least one approved biologic agent (bDMARDs) (including rituximab, abatacept, etanercept, belimumab, etc.), or targeted synthetic (ts) DMARDs (including tofacitinib, upadacitinib, baricitinib, abrocitinib, deucravacitinib, etc.) for treatment, with a total treatment duration of ≥3 months, yet still in an active disease state, ineffective, intolerant, or experiencing relapse during glucocorticoid tapering.
  5. No history of severe allergic reaction.
  6. Female participants of childbearing age must have a negative pregnancy test upon enrollment in the study; indeterminate results will not be accepted.
  7. Female subjects of childbearing age and male subjects with female partners of must agree to consistently use effective methods of within 6 months after the last KN5601 infusion.
  8. Echocardiography show that the heart structure is basically normal and the (LVEF) is ≥55%; no obvious abnormalities are found on the .
  9. Pulmonary function: No severe lung disease, SpO2 ≥ 92%.
  10. All subjects' eligibility for enrollment must be confirmed by an independent Assessment Committee (AC) (the committee consists of independent data monitors and clinical experts separate from the study). They will review the eligibility of each patient based on the scores entered at screening, as well as brief descriptions provided by the investigators regarding the supporting diagnosis, scores, and the patient's clinical status in relation to enrollment criteria..

Exclusion criteria

Exclusion Criteria:

  1. Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic (GC) for disease control during the period of the trial.
  2. within 5 years (except successfully treated in situ cancer, resected squamous cell or basal cell carcinoma of the skin.).
  3. During the screening visit, one of the following laboratory test values must be met, except for those caused by IgG4-RD.:

    1. Serum (AST) or alanine aminotransferase (ALT) greater than three times the (ULN).
    2. Total > two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin > three times ULN.
    3. White blood cell (WBC) count \<3.0×10⁹/L;
    4. (ANC) \<1.5×10⁹/L;
    5. \<90 g/L;
    6. count \<75×10⁹/L;
    7. Estimated (eGFR) ≤ 45 ml/(min·1.73m2).
  4. Evidence suggests the presence of another uncontrolled disease, which the investigator has determined may affect the subject's participation in the trial.
  5. Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization.
  6. Received rituximab or other B-cell depleting therapies within 6 months prior to the baseline visit, unless B cells have recovered (B-cell recovery is defined as peripheral blood B-cell count ≥ the lower limit of normal reference range or returned to pre-treatment levels)。
  7. The use of supplemental oxygen at baseline.
  8. During the screening visit or within 90 days prior to the screening visit: T-SPOT positive. If the result is indeterminate, the T-SPOT must be repeated (using the same or a different T-SPOT) and shown as negative.
  9. During screening visits, individuals with a history of chronic infection or serological evidence, including:

    1. infection;
    2. as indicated by surface antigen or hepatitis B core antibody positivity;
    3. as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at screening.
  10. Planned vaccination with during the trial.
  11. Participant is pregnant or breastfeeding, or planning a pregnancy while enrolled in the study.
  12. IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of

    1. retroperitoneal fibrosis,
    2. fibrosing mediatinitis,
    3. sclerosing mesenteritis, and
    4. Riedel's thyroiditis. Subjects were eligible to be included only if they had non-advanced fibrotic disease in at least one organ system and otherwise met the inclusion and exclusion criteria.
  13. Evidence a SARS-CoV-2 (COVID-19) infection started within the 30 days prior to treatment allocation/randomization. Participants diagnosed with SARS-CoV-2 (COVID-19) infection more than 30 days prior to treatment .allocation/randomization must have symptoms resolved and be deemed fit to participate in the trial.
  14. Researchers consider any situations that may increase the risk to participants or interfere with the trial results (including but not limited to a history of mental illness, alcoholism, drug abuse, poor compliance, etc.).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    This study is a single-arm, open-label and single-center exploratory clinical study

    Biological: CD19/BCMA CAR NK

Interventions

  • BiologicalCD19/BCMA CAR NK

    Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of CD19/BCMA CAR NK cells will infused using the dose-escalation strategy.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (DLT)

    To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: up to 48 weeks

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: up to 48 weeks

  3. The percentage of disease remission (Remission is defined as IgG4-RD RI=0 after treatment and without the use of hormones

    To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of disease remission of IgG4-RD RI score compared with baseline

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: 12, 24, 48 weeks

  2. Percentage of complete response, partial response, and no change (NC)

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: 12, 24, 48 weeks

  3. Disease recurrence rate

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: 24, 48 weeks after infusion

  4. Physician Global Assessment (PhGA) compared with baseline

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related disease

    Time frame: up to 48 weeks

  5. Patient Global Assessment (PGA) compared with baseline

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related disease

    Time frame: 12, 24, 48 weeks

  6. Disease-related Injury Score

    To characterize the safety of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: 12, 24, 48 weeks

  7. Health Survey by Health Status Questionnaire (SF-36)

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: up to 48 weeks

  8. Assessment of organ function compared with baseline based on MRl imaging

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: up to 48 weeks

  9. Assessment of the affected tissues and organs compared with baseline based on CT imaging examination

    To characterize the efficacy of CD19/BCMA CAR NK Cells (KN5601) for IgG4 related diseases

    Time frame: up to 48 weeks

  10. Assessment of persistence of KN5601 after infusion

    To detect CAR copy numbers of KN5601 in peripheral blood

    Time frame: up to 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Jun 2028, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 23, 2025
StartEst.
Dec 30, 2025
Primary completionEst.
Jun 26, 2028
CompletionEst.
Dec 26, 2028
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298590
Lead sponsor
Changhai Hospital
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Dec 30, 2025 (estimated)
Primary completion
Jun 26, 2028 (estimated)
Completion
Dec 26, 2028 (estimated)
Last update
Dec 23, 2025

Study contacts

Lei Xin
Contact
aip_xin@163.com
086-13817318134
Zhuan Liao
study chair · Changhai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion